AI Healthcare Stock Has Bullish Setup, Expert Says
Source: Clive Maund  (4/22/24)
Technical Analyst Clive Maund reviews Treatment.com AI's charts and the recent influx of news to explain why he believes it is a Strong Buy. More >

PDUFA Date Coming Up for U.K. Biopharma
Source: Edward Nash  (4/22/24)
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report. More >

Biopharma's New Drug for COPD Likely to be Approved
Source: Ram Selvaraju  (4/22/24)
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report. More >

New AI Solutions Set To Transform Medical Education and Clinical Practice
Source: Streetwise Reports  (4/19/24)
Treatment.com AI Inc., a leader in artificial intelligence for healthcare education, has introduced two new tools for its Medical Education Suite (MES). More >

Analyst Says Pharma Co. Has No True Competitor
Source: Andrew Tsai  (4/19/24)
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note. More >

LA Biotech's Lower Revenue Will Be Short Lived
Source: Dr. Jonathan Aschoff  (4/17/24)
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note. More >

Healthcare Co. Welcomes Possible AI Funding Effort in Canada
Source: Streetwise Reports  (4/9/24)
Canadian artificial intelligence (AI) and machine learning healthcare company Treatment.com AI Inc. is using AI to positively disrupt the healthcare sector. Canada is planning to fund the industry in a big way. More >

Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out
Source: Streetwise Reports  (4/8/24)
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high. More >

Co. Adding 500 Patients to Its Mental Health Care Platform
Source: Streetwise Reports  (4/3/24)
This Canada-based health care technology firm is profitable and growing. Learn more about it here. More >

Analyst Encouraged by ON Gov's Decision To Sustain Fees
Source: Dr. Douglas Loe  (4/2/24)
CareRx Corp. will continue to receive funding for professional fees at the same levels as before for at least one more year, according to a Leede Jones Gable research note. More >

Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Source: Streetwise Reports  (3/27/24)
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock. More >

AI Co. Funded To Develop AI Approach to Health Equity
Source: Streetwise Reports  (3/27/24)
Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock. More >

AI Medical App Passes Standard Student Test
Source: Streetwise Reports  (3/26/24)
This software is one of a suite offered by this health care technology firm. Learn about its other products and the growing sector. More >

Healthcare Stock Has Reasonable Value Before Seasonal Profit, Analyst Says
Source: Dr. Douglas Loe  (3/26/24)
K-Bro Linen Inc.'s FQ23 financial data supported its Buy rating, according to a Leede Jones Gable research note. More >

Biotech Co.'s Target Price Significantly Higher Than Current
Source: Dr. Jonathan Aschoff  (3/19/24)
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note. More >

Biotech Stocks Break Out
Source: Ron Struthers  (3/19/24)
Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into. More >

Is This Pharma Set To Break Out After COPD Drug Approval?
Source: Streetwise Reports  (3/15/24)
Clinical-stage biopharmaceutical company Verona Pharma Plc is looking toward a pivotal year as its new chronic obstructive pulmonary disease (COPD) drug ensifentrine nears possible approval by the FDA. At least two research companies have named it a top pick for 2024. More >

This Biotech Is a Potential Disruptor, Expert Says
Source: Chris Temple  (3/12/24)
Chris Temple of The National Investor shares why he believes BetterLife Pharma Inc. is an Immediate Buy. More >

Wellness Co.'s New Initiatives Should 'Lower Barriers' Analysts Say
Source: George Kelly  (3/12/24)
The Beachbody Company Inc.'s 4Q23 results have Roth MKM analysts maintaining their Buy rating. More >

Safe Supply Firm Announces Another Promising Acquisition
Source: Streetwise Reports  (3/11/24)
Safe Supply Streaming Co. adds another company to its portfolio, and continues advocating for harm reduction in the psychedelic sector. More >

Healthcare AI Firm Has 'Bright Future,' Analyst Predicts
Source: Streetwise Reports  (3/8/24)
Canadian artificial intelligence (AI) and machine learning healthcare firm Treatment.com AI is breaking into the global healthcare AI market predicted to be worth US$187 billion by the end of the decade. More >

NY Biotech Has Potentially Game Changing Anxiety Therapy
Source: Dr. Jonathan Aschoff  (3/7/24)
Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note. More >

Bionic Medical Co. Has Sufficient Funds to Operate Through 2024
Source: Dr. Swayampakula Ramakanth  (3/5/24)
Ekso Bionics Holdings Inc.'s fourth quarter of 2023 financial results were in line with estimates, according to H.C. Wainwright & Co. More >

'Safe Supply' Co. Secures Legal Flow of Coca Products
Source: Streetwise Reports  (2/20/24)
This is a milestone for the venture capital firm investing in efforts that address the toxic drug crisis in Canada and the U.S. Learn more about the company and the latest wave of drug reform. More >

Alt-Pharma VC adds 7% Stake in Testing Strip Firm
Source: Streetwise Reports  (2/15/24)
Alt pharma is hot these days, and few companies are coming in hotter than Safe Supply Streaming Co. Ltd., which just secured a 7% stake in a leading medical test company to expand its functional portfolio. More >